Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

home / authors / elizabeth-o-donnell-md

Articles

Experts on MM

Induction Therapy Regimens for Transplant-Eligible NDMM

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute
June 27th 2023

Key opinion leaders on multiple myeloma management review available induction therapy regimens in the transplant-eligible setting.

Read More

Expert on MM

NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute
June 20th 2023

Comprehensive insight on patient and disease characteristics that help to inform best available therapy for patients with newly diagnosed multiple myeloma.

Read More

Experts on MM

What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute
June 20th 2023

Expert panelists reflect on the continuing role of stem cell transplant in patients with newly diagnosed multiple myeloma.

Read More

<12

Latest Updated Articles

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for medical oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show
Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer